Ipamorelin

Ipamorelin's defining advantage is selectivity. In direct comparisons, GHRP-6 and GHRP-2 raise cortisol and ACTH alongside GH. Ipamorelin produces no significant cortisol or ACTH elevation even at doses 200× above its GH-releasing ED₅₀ — making it far more hormonal-profile-friendly for long-term protocols.

Sermorelin is a truncated GHRH analog that stimulates GH via the GHRH receptor; ipamorelin works on the ghrelin/GHS-R1a receptor. Their downstream effects overlap substantially, but the receptor pathways are different. Stacking them produces additive GH release. Sermorelin has a longer published clinical history; ipamorelin's selectivity profile is generally considered cleaner.

CJC-1295 (no DAC) acts on the GHRH receptor, while ipamorelin acts on the ghrelin receptor. Activating both simultaneously is synergistic — combined GH output is 2-3× greater than either peptide alone. The combination also more faithfully mimics the natural dual-signal pulsatile GH release that occurs endogenously.

No. Because ipamorelin has a short half-life (~2 hours) and produces pulse-based GH release rather than sustained elevation, pituitary GHS-R1a receptors retain normal sensitivity between doses. Endogenous GH secretion resumes without suppression once the peptide clears, unlike exogenous recombinant GH.

GH secretion peaks within 15-30 minutes of subcutaneous injection and returns to baseline within approximately 2 hours. Downstream IGF-1 elevation — the proxy for anabolic and recovery effects — rises gradually over days to weeks of consistent use. Most users report sleep quality and recovery improvements within 2-4 weeks.

Yes — this is one of the most cited reasons for use. The largest endogenous GH pulse naturally occurs during slow-wave sleep; ipamorelin amplifies this nocturnal pulse and may independently deepen sleep architecture through hypothalamic GHS-R1a signaling. Dosing before bed is standard in published protocols.

Mild water retention is a reported side effect, attributed to GH's physiological action on renal sodium and water reabsorption. It typically resolves within days of dose reduction or cessation. Because ipamorelin does not raise cortisol (unlike GHRP-2 or GHRP-6), cortisol-driven fluid retention is not a compounding factor.

Growth hormone peptides including ipamorelin are prohibited under the WADA Prohibited List (Section S2, Peptide Hormones and GH Secretagogues). Detection methods using liquid chromatography-mass spectrometry have been validated for GH-releasing peptides. Competitive athletes in tested sports should consider ipamorelin prohibited regardless of jurisdiction.

Both activate GHS-R1a, but MK-677 is orally bioavailable and sustains receptor activation continuously, producing a tonic rather than pulsatile GH elevation. Ipamorelin creates discrete 2-hour GH pulses that preserve receptor sensitivity and circadian GH rhythms. MK-677 more commonly causes appetite stimulation and water retention due to continuous ghrelin mimicry.

The relevant study is Johansen et al. (Growth Horm IGF Res, 1999), in adult female rats dosed subcutaneously three times daily for 15 days. Ipamorelin dose-dependently increased longitudinal bone growth rate in the proximal tibia metaphysis, from 42 µm/day in vehicle to 52 µm/day at the top dose, along with dose-dependent body weight gain. Importantly, the effect was not IGF-1-mediated: the treatment did not affect total IGF-I levels, IGF binding proteins, or serum markers of bone formation and resorption, and the study included no GHRP-6 comparator. Bone mineral density was not measured, in this study or any other, and no controlled human bone or body-composition trial of ipamorelin exists.